- Updates
on CBD patents and medical device progress
- Working
to improve medical treatments on a global scale through its subsidiaries
- Moving
toward uplisting to the OTCQB Venture Market
Earth Science Tech, Inc. (OTC: ETST), based in Doral,
Florida, is a biotechnology company focused on cannabis, industrial hemp and
cannabinoid research and development, including the commercialization of
nutraceuticals, pharmaceuticals and medical devices. The company is working to
improve medical treatments on a global scale for different diseases through its
subsidiaries: Earth Science Pharmaceutical, Cannabis Therapeutics Inc.,
Kannabidioid Inc. and Canna Inno Laboratories Inc.
ETST is in the final phases of preparation for uplisting to
the OTCQB Venture Market. This move is expected to boost investor confidence
and open additional opportunities. “Transparency is a key tool that we needed
to accelerate the growth of our business,” Dr. Michel Aube, CEO and chief
science officer of ETST, stated in a recent news release (http://ibn.fm/AB0vq). “Since all
of our amazing projects are ongoing with our partners, investor confidence will
grow, and we will be able to complete our first big round of financing. We are
in touch with institutional and private investors that were waiting for ETST to
become a fully reporting company before investing the necessary amount to
commercialize our projects. We can now resume our discussions with them.” ETST
will continue to share updates on the full reporting process as it progresses.
In a recent news release (http://ibn.fm/S8xTD), the company shared updates on its
ongoing CBD formula patents and medical device progress. Earlier this year,
ETST announced that it received a grant from the Government of Quebec to develop
three new CBD-based products. The prototyping on these products has now begun.
The function of these products is to maintain quality of life and prevent
inflammation, cancer and degenerative diseases. The MSN-2, a medical device
developed to prevent chlamydia and other sexually transmitted infections, is in
its final stage prior to the launch.
“The official launch of this medical device is a little like
giving birth,” Aube stated. “It will be unique in the marketplace and we are
branding this device globally. We will create a strong demand for this medical
device by showing the world its powerful capacity to diminish the prevalence of
chlamydia and other Sexually Transmitted Infections.”
ETST is working with Accélération, Design et Innovation Inc.
on final packaging designed to target a global audience of women, and the
company is in the process of securing trademark protection for the logo and
name. The device is dedicated to improving the health of women worldwide.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
